Clearmind Medicine Inc

Clearmind Medicine Inc (CMND) Stock Analysis

$1.760

-0.049 (-2.76%)At close

Loading chart…
High
1.840
Open
1.820
VWAP
1.78
Vol
24.79K
Mkt Cap
4.44M
Low
1.730
Amount
44.04K
EV/EBITDA, TTM
0.00

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.

www.clearmindmedicine.com

AI analysis of Clearmind Medicine Inc (CMND)

hold

Clearmind Medicine Inc is currently trading at $1.76, which is significantly down 91.16% year-to-date and 99.58% over the past year, indicating a strong decline in value. The stock has a current RSI of 49.87, suggesting it is neither overbought nor oversold, but the negative earnings per share (EPS) of -328.38 and a forward P/E ratio of 0 indicate ongoing financial struggles. While recent news about patent applications for MDMA combinations shows potential for future growth, the risks associated with its current financial performance and lack of profitability make it a hold rather than a buy at this time.

Valuation Metrics

The current forward P/E ratio for Clearmind Medicine Inc (CMND) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
Overvalued
0.00
Undervalued
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued
0.00
Undervalued
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
Overvalued
0.00
Undervalued
0.00

Alphio AI Price Scenarios for CMND

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%CMND

$0.98

Scenario price

B

Base

Base · 50%CMND

$0.98

Scenario price

B

Bear

Bear · 25%CMND

$0.80

Scenario price

Events Timeline

2026-08-24 (ET)

09:30:00

SciSparc Subsidiary and Clearmind File New Patent Application

2026-08-13 (ET)

11:30:00

Definium Therapeutics Reports DT120 ODT Phase 3 Study Results, RBC Raises Price Target to $66

09:30:00

Clearmind Medicine Advances CMND-100 Clinical Trial to Parts B and C

2026-08-11 (ET)

08:30:00

Clearmind Medicine Announces MEAI Intranasal Study Results

2026-08-06 (ET)

10:30:00

Compass Pathways Q2 Loss Widens to 34 Cents

Show More Events

News

Show More News

CMND FAQ — answered by Alphio AI

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Clearmind Medicine Inc is currently trading at $1.76, which is significantly down 91.16% year-to-date and 99.58% over the past year, indicating a strong decline in value. The stock has a current RSI of 49.87, suggesting it is neither overbought nor oversold, but the negative earnings per share (EPS) of -328.38 and a forward P/E ratio of 0 indicate ongoing financial struggles. While recent news about patent applications for MDMA combinations shows potential for future growth, the risks associated with its current financial performance and lack of profitability make it a hold rather than a buy at this time.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started